10-Q: Acro Biomedical Faces Going Concern Doubts Amid Zero Revenue

Acro Biomedical Co., Ltd. reported no revenue for Q1 2025, continued operating losses, and significant doubt about its ability to continue as a going concern, relying heavily on related party advances.

Summary

• No revenue generated for the three months ended March 31, 2025, or since December 31, 2022.
• Net loss for Q1 2025 was $10,301, an improvement from $11,252 in Q1 2024, primarily due to lower operating expenses.
• Cash balance remains minimal at $251 as of March 31, 2025.
• Working capital deficiency worsened to $(324,230) from $(321,870) at December 31, 2024.
• Cash used in operating activities increased to $(22,531) in Q1 2025 from $(13,513) in Q1 2024.
• The company relies entirely on advances from a minority stockholder and its CEO for funding operations.
• Substantial doubt exists about the company's ability to continue as a going concern.
• Common stock trades on the OTC Market Group's Expert Market, limiting liquidity and public visibility.

Sentiment

Score: 1

Explanation: The company faces severe financial distress with no revenue, increasing losses, a worsening working capital deficit, and substantial doubt about its ability to continue as a going concern. Its reliance on related party funding, ineffective internal controls, and limited market access for its stock paint a dire picture.

Positives

• Net loss decreased to $10,301 in Q1 2025 from $11,252 in Q1 2024, indicating slightly reduced operating expenses.
• Cash balance at the end of the period increased slightly to $251 from $151 year-over-year, though still minimal.

Negatives

• No revenue generated for the three months ended March 31, 2025, or since December 31, 2022.
• Continued operating losses and negative cash flow from operations.
• Working capital deficiency worsened to $(324,230) as of March 31, 2025.
• Total stockholders' deficit increased to $(303,906) as of March 31, 2025.
• Heavy reliance on related party advances for funding, with no assurance of continued support.
• Common stock trades on the OTC Expert Market, meaning no public quotes or market makers, severely limiting liquidity and ability to raise equity.
• Material weaknesses in internal controls over financial reporting due to lack of segregation of duties and qualified accounting personnel.
• Disclosure controls were deemed ineffective as of March 31, 2025.
• Past research and development activities (cordyceps-infused chicken feed) did not generate a marketable product.
• Delinquent in filings with the SEC, further hindering fundraising efforts.

Risks

• Inability to generate revenue from products, potentially leading to business cessation.
• Inability to raise necessary financing through debt, equity, or loan facilities.
• Difficulty increasing customer base and supply chain.
• Inability to increase gross margins.
• Challenges in hiring and retaining qualified personnel (R&D, marketing, administrative).
• Failure to develop and market new products, especially in Western markets.
• Non-compliance with government regulations for product manufacture, distribution, and marketing.
• Impact of political instability in Hong Kong on sales, as past customers were Hong Kong-based selling into the PRC.
• Inflationary pressures and supply chain disruptions affecting product costs and delivery.
• Aftereffects of COVID-19 restrictions and China's Zero-COVID policy on customer ability to pay and the Chinese economy.
• Lack of an active market for common stock and its trading on the OTC Expert Market, making equity fundraising difficult and potentially dilutive.
• Reliance on a single minority stockholder for funding, with no assurance of continued support.
• Material weaknesses in internal controls over financial reporting due to lack of segregation of duties and qualified accounting personnel.
• Delinquency in SEC filings.

Future Outlook

The company proposes to fund operations through product sales and equity financing, but currently has no product orders and faces significant challenges in raising equity due to its financial condition and stock market status. There is no assurance of developing marketable products or generating future revenue or profits. The company may rely on equity-based compensation or loans from stockholders/related parties, but no agreements are in place.

Management Comments

• "Although forward-looking statements in this report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by us."
• "We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report, except as required by law."
• "We believe that, since a major market for cordyceps products is China, our customers have significant customers in China and our business was impacted by COVID-19 and steps taken by the government of China, particularly its Zero COVID policy, which was relaxed in December 2022."
• "We cannot assure you that these factors will not affect our ability to generate revenue in the future and, to the extent that any of these factors affect our ability to generate revenue, we may not be able to continue in business."
• "Our selling, general and administrative expenses do not include any compensation for our chief executive officer, who serves without compensation and is responsible for our purchases, sales and directed our research and development program. As a result, the results of our operations do not reflect costs that would normally be associated with a chief executive officer who performs such functions."
• "Our inability to generate sales partially resulted from the aftereffects of the COVID-19 restrictions of the Chinese government. Our customers suffered tremendous financial losses due to COVID-19 restrictions, including the Chinese government's No-COVID policy."

Industry Context

Acro Biomedical operates in the nutritional products sector, specifically focusing on cordyceps-related products, which are traditionally used in Chinese medicine. The company's historical reliance on the Chinese market makes it highly susceptible to economic and political conditions in China and Hong Kong, as evidenced by the impact of COVID-19 policies. The broader industry for health supplements and traditional medicine is competitive, but Acro Biomedical's current lack of revenue, R&D failures, and inability to secure external financing place it far behind any established or emerging competitors.

Comparison to Industry Standards

• Acro Biomedical's complete lack of revenue since December 2022 is significantly below industry standards for operational companies in the nutritional products sector, which typically demonstrate consistent sales.
• The company's reliance on a single part-time, unpaid CEO/CFO and related party advances for all funding is highly unusual and unsustainable compared to well-governed public companies that secure diverse funding and maintain robust management teams.
• The failure of its cordyceps-infused chicken feed R&D project, coupled with no funds for future R&D, contrasts sharply with industry leaders like Herbalife Nutrition or GNC, which continuously invest in product innovation and market expansion.
• The company's stock trading on the OTC Expert Market, with no public quotes or market makers, is a severe disadvantage compared to most publicly traded companies, which aim for listing on major exchanges to ensure liquidity and investor access.
• The disclosed material weaknesses in internal controls and ineffective disclosure controls are far below the corporate governance standards expected of any public company, especially when compared to peers subject to Sarbanes-Oxley compliance.

Management Changes

Corporate Governance

Related Party Transactions

• A minority stockholder advanced $22,306 to the company during Q1 2025 (Q1 2024: $13,288) by paying expenses on its behalf.
• As of March 31, 2025, the company owed $146,794 to this minority stockholder for non-interest-bearing advances/expenses paid, due on demand.
• As of March 31, 2025, the company owed $1,100 to its Chief Executive Officer for non-interest-bearing advances/expenses paid, due on demand.
• Imputed interest of $1,367 (Q1 2025) and $954 (Q1 2024) was recognized on these related party advances at a 4% rate.
• The security deposit and monthly rent for the Hong Kong storage facility lease were paid by a minority stockholder on behalf of the company.

Stakeholder Impact

• Shareholders: Face significant dilution if equity financing is pursued, severe liquidity issues due to OTC Expert Market trading, and substantial risk of losing investment due to going concern doubts and lack of business operations.
• Employees: Currently only one part-time, unpaid CEO/CFO, indicating no significant impact on a broader employee base. Potential future employees/consultants may be reluctant to accept equity compensation due to stock market status.
• Creditors: Primarily related parties (minority stockholder, CEO) who are providing non-interest-bearing, on-demand advances, indicating high risk for any external creditors.
• Customers: No current customers or orders, so no direct impact. Past customers in China were affected by COVID-19 policies, leading to payment issues.
• Suppliers: No current inventory purchases or sales, so no direct impact. Future suppliers would face high payment risk.

Next Steps

• Seek to generate revenue from product sales.
• Pursue equity financing arrangements.
• Potentially market other products complementary to current offerings.
• Address material weaknesses in internal controls over financial reporting.
• Continue to rely on advances from a minority stockholder and an officer for funding.

Key Dates

Recommendation

Acro Biomedical presents an extremely high-risk investment profile. The company has generated no revenue for over two years, operates at a loss, and has a worsening working capital deficit. Management explicitly states 'substantial doubt about the Company's ability to continue as a going concern.' Its sole funding source is related party advances, which are not guaranteed. The stock trades on the illiquid OTC Expert Market, making it nearly impossible for public investors to buy or sell. Furthermore, severe internal control weaknesses and ineffective disclosure controls indicate significant operational and governance failures. There is no clear path to profitability or sustainable operations, making the stock a strong sell for any investor.

Keywords

Acro Biomedical, cordyceps, biomedical, nutritional products, SEC filing, 10-Q, going concern, OTC Expert Market, related party transactions, financial reporting, internal controls, biotech, health supplements